Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Accured Expenses: 2010-2024

Historic Change in Accured Expenses for CorMedix (CRMD) over the last 10 years, with Dec 2024 value amounting to $23.0 million.

  • CorMedix's Change in Accured Expenses rose 484.49% to $54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.5 million, marking a year-over-year increase of 791.75%. This contributed to the annual value of $23.0 million for FY2024, which is 667.41% up from last year.
  • Per CorMedix's latest filing, its Change in Accured Expenses stood at $23.0 million for FY2024, which was up 667.41% from $3.0 million recorded in FY2023.
  • In the past 5 years, CorMedix's Change in Accured Expenses ranged from a high of $23.0 million in FY2024 and a low of $961,963 during FY2022.
  • In the last 3 years, CorMedix's Change in Accured Expenses had a median value of $3.0 million in 2023 and averaged $9.0 million.
  • As far as peak fluctuations go, CorMedix's Change in Accured Expenses crashed by 42.54% in 2021, and later soared by 667.41% in 2024.
  • Yearly analysis of 5 years shows CorMedix's Change in Accured Expenses stood at $1.9 million in 2020, then slumped by 42.54% to $1.1 million in 2021, then declined by 11.10% to $961,963 in 2022, then spiked by 211.35% to $3.0 million in 2023, then skyrocketed by 667.41% to $23.0 million in 2024.